9 METERS BIOPHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 10
- Market Cap
- -
- Website
- http://9meters.com
VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.
Phase 2
Terminated
- Conditions
- Short Bowel Syndrome
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04988997
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
Proof of Concept Study in Patients With Short Bowel Syndrome
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04379856
- Locations
- 🇺🇸
Research Facility One, Los Angeles, California, United States
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 307
- Registration Number
- NCT03569007
- Locations
- 🇺🇸
Research Site, Wauwatosa, Wisconsin, United States
A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
- First Posted Date
- 2011-07-18
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 342
- Registration Number
- NCT01396213
Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease
Phase 2
Completed
- Conditions
- Celiac Disease
- Interventions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00889473
- Locations
- 🇨🇦
Study Site, Edmonton, Alberta, Canada
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT00620451
- Locations
- 🇪🇸
Study Site, Valladolid, Spain
🇪🇸Study site, Madrid, Spain
Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease
Phase 2
Completed
- Conditions
- Celiac Disease
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT00492960
- Locations
- 🇨🇦
Study Site, Winnipeg, Canada
Safety of Larazotide Acetate in Healthy Volunteers
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00386490
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
Safety Study of Larazotide Acetate to Treat Celiac Disease.
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00386165
- Locations
- 🇺🇸
Parexel, Baltimore, Maryland, United States
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- 9 Meters Biopharma, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00362856
- Locations
- 🇺🇸
Research Site, Richmond, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath